JP2589088B2 - Determination of anti-streptolysin O - Google Patents

Determination of anti-streptolysin O

Info

Publication number
JP2589088B2
JP2589088B2 JP62169498A JP16949887A JP2589088B2 JP 2589088 B2 JP2589088 B2 JP 2589088B2 JP 62169498 A JP62169498 A JP 62169498A JP 16949887 A JP16949887 A JP 16949887A JP 2589088 B2 JP2589088 B2 JP 2589088B2
Authority
JP
Japan
Prior art keywords
aso
absorbance
slo
change
nonionic surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP62169498A
Other languages
Japanese (ja)
Other versions
JPS6413461A (en
Inventor
貴幸 田中
昌志 関
英昭 柴田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissui Pharmacetuical Co Ltd
Original Assignee
Nissui Pharmacetuical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissui Pharmacetuical Co Ltd filed Critical Nissui Pharmacetuical Co Ltd
Priority to JP62169498A priority Critical patent/JP2589088B2/en
Publication of JPS6413461A publication Critical patent/JPS6413461A/en
Application granted granted Critical
Publication of JP2589088B2 publication Critical patent/JP2589088B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Description

【発明の詳細な説明】 〔産業上の利用分野〕 本発明は抗ストレプトリジンO(以下「ASO」と略称
する)の定量法に関し、更に詳細には、免疫比濁法を改
良した、自動分析に適するASOの定量法に関する。
The present invention relates to a method for quantifying anti-streptolysin O (hereinafter abbreviated as "ASO"), and more particularly, to an automated immunoturbidimetric assay which is an improved immunoturbidimetric assay. To a method for quantifying ASO suitable for

〔従来の技術〕[Conventional technology]

ストレプトリジンO(以下「SLO」と略称する)はヒ
ト由来連鎖球菌の産生する溶血性毒素であり、抗原性を
有するため、体内で溶連菌がSLOを産生するとこれに対
する抗体であるASOが生成される。従つて、例えば血清
中のASO量を測定することにより、連鎖球菌感染症、こ
とにその続発疾患とされているリウマチ熱、急性糸球体
腎炎などの診断が可能である。
Streptolysin O (hereinafter abbreviated as "SLO") is a hemolytic toxin produced by human-derived streptococci and has antigenicity. When streptococcus produces SLO in the body, ASO, an antibody against it, is produced. . Therefore, for example, by measuring the amount of ASO in serum, it is possible to diagnose streptococcal infections, particularly rheumatic fever and acute glomerulonephritis, which are secondary diseases thereof.

従来、ASOを測定する方法としては、抗原であるSLOが
検体血清中の抗体であるASOと反応し、毒素活性が中和
されることを利用してASOを測定するランツランダール
法及びマイクロタイター法;抗原であるSLOを担体ラテ
ツクスに感作し、抗原抗体反応をラテツクスの凝集とし
て自動分析機により検出してASOを測定するラテツクス
比濁法;スライドグラス上でASOとSLOを抗原抗体反応せ
しめ、生じた凝集の量を肉眼により観察してASOを測定
するラテツクススライド凝集法等が採用されてきた。
Conventionally, methods for measuring ASO include the Landzlandal method and the microtiter method, which measure ASO by utilizing the fact that SLO, which is an antigen, reacts with ASO, which is an antibody in sample serum, and neutralizes toxin activity. Method: Lattex turbidimetric method, in which SLO, which is an antigen, is sensitized to carrier latex, and antigen-antibody reaction is detected as latex agglutination by an automatic analyzer to measure ASO; ASO and SLO are reacted on a slide glass by antigen-antibody A latex slide agglutination method of observing the amount of agglutination with the naked eye and measuring ASO has been employed.

〔発明が解決しようとする問題点〕[Problems to be solved by the invention]

しかしながら、ランツランダール法及びマイクロタイ
ター法は実施に際してウサギ、ヒツジまたはヒトO型赤
血球を必然的に必要とし、しかも赤血球は新鮮なもので
なければ測定値にバラツキを生じてしまうという欠点が
あつた。また測定法自体も煩雑であり、反応時間も1時
間30分と比較的長いため測定の自動化が困難であること
などの問題がある。
However, the Lanzlandal method and the microtiter method necessarily require rabbit, sheep or human type O erythrocytes to be carried out, and have the disadvantage that if the erythrocytes are not fresh, the measured values will vary. . In addition, the measurement method itself is complicated, and the reaction time is relatively long, that is, 1 hour and 30 minutes. Therefore, there is a problem that automation of the measurement is difficult.

また、ラテツクス比濁法はラテツクスの非特異的凝集
により測定値がばらついたり、試薬の乾燥により自動分
析機が詰まるなどの問題がある。
In addition, the latex turbidimetric method has problems in that the measured values vary due to non-specific aggregation of the latex, and that the automatic analyzer is clogged due to drying of the reagent.

更に、ラテツクススライド凝集法も目視による方法で
あるため、測定の自動化が困難であるという問題を有し
ている。
Furthermore, since the latex slide agglutination method is also a visual method, there is a problem that it is difficult to automate the measurement.

従つて、精度が高く、現在汎用の生化学用自動分析機
に好適に適用できるASOの定量法の開発が望まれてい
た。
Therefore, there has been a demand for the development of a method for quantifying ASO which has high accuracy and can be suitably applied to a general-purpose biochemical automatic analyzer at present.

〔問題点を解決するための手段〕[Means for solving the problem]

本発明者らは上記問題点を解決すべく鋭意検討を行な
つたところ、フェニル基を有するポリオキシエチレンエ
ーテル系非イオン性界面活性剤(以下、単に「非イオン
性界面活性剤」と称する)を凝集促進剤として使用し、
抗原抗体反応開始後の凝集発生による吸光度変化を測定
すれば、容易にかつ高精度でASOが測定できること及び
この方法は自動分析機に有利に適用し得るものであるこ
とを見出し、本発明を完成した。
The present inventors have conducted intensive studies to solve the above-mentioned problems, and found that a polyoxyethylene ether-based nonionic surfactant having a phenyl group (hereinafter, simply referred to as “nonionic surfactant”). Is used as an aggregation promoter,
Completed the present invention by finding that ASO can be measured easily and with high accuracy by measuring the change in absorbance due to the occurrence of aggregation after the start of the antigen-antibody reaction, and that this method can be advantageously applied to an automatic analyzer. did.

すなわち、本発明は検体にSLO及び非イオン性界面活
性剤を添加し、生じた凝集による吸光度変化量を測定す
ることを特徴とするASOの定量法である。
That is, the present invention is a method for quantifying ASO, which comprises adding SLO and a nonionic surfactant to a sample, and measuring the amount of change in absorbance due to the resulting aggregation.

本発明を実施するには、まず、ASOを含む検体中に好
ましくは過剰のSLO及び非イオン性界面活性剤を添加す
る。
In practicing the present invention, first, preferably, an excess of SLO and a nonionic surfactant are added to a sample containing ASO.

検体としては、各種体液が用いられるが、一般には血
清が好ましい。また、SLOとASOとの凝集反応系の好まし
い温度範囲は室温ないし40℃程度、pH範囲は4.5〜8.5で
あるので、本発明の実施には反応系をこの条件に適合さ
せることが必要である。なお、SLO及び非イオン性界面
活性剤の添加時及びその後においては、系が均一となる
よう撹拌をおこなうことが必要である。更に本発明にお
いて用いられる非イオン性界面活性剤は、例えばそのHL
B値が13〜20以上のものが特に好ましい。より具体的に
は例えばポリオキシエチレンオクチルフエニルエーテル
(EO=30〜100のもの)、ポリオキシエチレンノニルフ
エニルエーテル(EO=30〜100のもの)、などが挙げら
れ、これらは単独でまたは組み合わせて使用することが
できる。
Various body fluids are used as the specimen, and serum is generally preferred. Further, the preferred temperature range of the agglutination reaction system between SLO and ASO is from room temperature to about 40 ° C., and the pH range is from 4.5 to 8.5. Therefore, it is necessary to adapt the reaction system to these conditions in order to practice the present invention. . At the time of adding the SLO and the nonionic surfactant and thereafter, it is necessary to perform stirring so that the system becomes uniform. Further, the nonionic surfactant used in the present invention is, for example, its HL
Those having a B value of 13 to 20 or more are particularly preferred. More specifically, for example, polyoxyethylene octyl phenyl ether (EO = 30 to 100), polyoxyethylene nonyl phenyl ether (EO = 30 to 100), and the like, and these can be used alone or They can be used in combination.

また、SLO及び非イオン性界面活性剤の検体への添加
は、同時に行なつても、あらかじめ非イオン性界面活性
剤を加えておいた検体中へSLOを添加しても、いずれで
も良く、これらの添加量は、一般には、SLOが検体100μ
当り200〜1,000単位以上、非イオン性界面活性剤が2
〜20重量%程度である。
The addition of the SLO and the nonionic surfactant to the sample may be performed simultaneously, or the SLO may be added to the sample to which the nonionic surfactant has been added in advance. In general, the amount of SLO
200 to 1,000 units or more per nonionic surfactant
About 20% by weight.

次いで、抗原抗体反応で生じる凝集による吸光度変化
量が測定される。
Next, the amount of change in absorbance due to aggregation caused by the antigen-antibody reaction is measured.

本発明方法で用いる測定波長は一般には300〜400nmで
ある。また、反応開始直後の凝集生成の著しい時期にお
いての吸光度の変化を測定することが重要であるので、
一般には反応開始後5〜7分までに、好ましくは反応開
始後3分以内に吸光度測定を終了させることが望まし
い。また、測定用機器としては、光度計を有する汎用の
自動分析機であればよく、特に限定されない。なお、本
発明方法においてより精度を高めるためには、単位時間
当りの吸光度変化の測定値から最小二乗法により吸光度
変化量を求めれば良い。
The measurement wavelength used in the method of the present invention is generally 300 to 400 nm. Also, since it is important to measure the change in absorbance at the time of significant aggregation formation immediately after the start of the reaction,
Generally, it is desirable to terminate the absorbance measurement within 5 to 7 minutes after the start of the reaction, preferably within 3 minutes after the start of the reaction. The measuring instrument is not particularly limited as long as it is a general-purpose automatic analyzer having a photometer. In order to further improve the accuracy in the method of the present invention, the amount of change in absorbance may be obtained from the measured value of change in absorbance per unit time by the least square method.

最後に、検量線を用いることにより、吸光度変化量か
らASO量が測定される。
Finally, the ASO amount is measured from the absorbance change amount by using the calibration curve.

検量線は、ASOを含まない検体液、例えばASOを含まな
い標準血清と、濃度既知のASOを用いることにより容易
に調製される。
The calibration curve is easily prepared by using a sample solution containing no ASO, for example, a standard serum containing no ASO, and ASO having a known concentration.

本発明方法を容易に実施するためには、本方法を実施
するために必要な成分、すなわち、必須成分であるSLO
及び非イオン性界面活性剤のほか、検体のpHを一定範囲
に保ち、濁りを防ぐための緩衝液、防腐剤、無機塩等を
含有する分析試薬用キツトを利用すると有利である。
In order to easily carry out the method of the present invention, components necessary for carrying out the method, that is, SLO which is an essential component
It is advantageous to use a kit for an analytical reagent containing a buffer, a preservative, an inorganic salt and the like for keeping the pH of the specimen within a certain range and preventing turbidity, in addition to the nonionic surfactant and the nonionic surfactant.

このような分析試薬用キツトの一例を示せば次の通り
である。
An example of such an analysis reagent kit is as follows.

第1試薬: 非イオン性界面活性剤 2〜20 重量% 防腐剤 0〜0.2重量% 無機塩(NaCl、リン酸ナトリウム等) 0.5〜3 重量% 精製水 バランス (緩衝液を用い、pHを5.5〜8.0に保持する) 第2試薬: SLO 1,000〜10,000単位/ml 非イオン性界面活性剤 2〜20 重量% 防腐剤 0〜0.2重量% 無機塩等 0.5〜3 重量% 精製水 バランス (緩衝液を用い、pHを5.5〜8.0に保持する) 〔発明の効果〕 本発明の定量法は、ラテツクス等の担体や赤血球を用
いないため、赤血球の種類や鮮度に依存する誤差の発生
や、ラテツクスなどの担体の非特異的凝集による測定値
のバラツキがなく、また、一定時間経過後の吸光度の差
でなく反応初期の吸光度変化量を測定するものであるた
め、高い精度でASOを定量することが可能である。ま
た、凝集促進剤の添加により、凝集時間が5〜10分程度
に短縮されるため、現在汎用の生化学用自動分析機に適
用することができる。更に凝集促進剤として非イオン性
界面活性剤を使用しているため、反応セルや試薬分注機
構の洗浄の手間が軽減され、自動分析機の光学的部分や
試薬分注機構も保護される。
First reagent: Nonionic surfactant 2 to 20% by weight Preservative 0 to 0.2% by weight Inorganic salt (NaCl, sodium phosphate, etc.) 0.5 to 3% by weight Purified water balance (using a buffer solution to adjust the pH to 5.5 to Second reagent: SLO 1,000 to 10,000 units / ml Nonionic surfactant 2 to 20% by weight Preservatives 0 to 0.2% by weight Inorganic salts etc. 0.5 to 3% by weight Purified water balance (using a buffer solution) [Effect of the Invention] Since the quantification method of the present invention does not use a carrier such as a latex or an erythrocyte, an error depending on the type and freshness of the erythrocyte is generated, and a carrier such as a latex is used. Since the measured values do not vary due to non-specific aggregation of ASO and the change in absorbance at the beginning of the reaction is measured instead of the difference in absorbance after a certain period of time, ASO can be quantified with high accuracy. is there. Further, the addition of the coagulation accelerator shortens the coagulation time to about 5 to 10 minutes, so that the present invention can be applied to general-purpose biochemical automatic analyzers. Further, since a nonionic surfactant is used as the aggregation promoter, the labor for cleaning the reaction cell and the reagent dispensing mechanism is reduced, and the optical portion of the automatic analyzer and the reagent dispensing mechanism are protected.

〔実施例〕〔Example〕

以下に実施例を挙げて説明するが、本発明はこれに限
定されるものではない。
Hereinafter, the present invention will be described with reference to Examples, but the present invention is not limited thereto.

実施例 143検体の血清について下記の操作方法及び標準検量
線を用いASOを求めた。一方、これらの検体血清につい
てラテツクス比濁法及びマイクロタイター法によつても
ASOを求め、これら方法と本発明方法の相関関係を調べ
た。
Example 143 ASO was determined for the serum of 143 samples using the following operation method and standard calibration curve. On the other hand, these sample sera were also determined by latex turbidimetry and microtiter method.
ASO was determined and the correlation between these methods and the method of the present invention was examined.

本発明方法とラテツクス比濁法との相関図を第3−A
図、本発明方法とマイクロタイター法との相関図を第3
−B図に示す。
The correlation diagram between the method of the present invention and the latex turbidimetric method is shown in FIG.
FIG. 3 shows a correlation diagram between the method of the present invention and the microtiter method.
FIG.

(1) 使用機器 日立7050型自動分析装置 (2) 試薬 (i)第1試薬 HEPES緩衝液(pH7.2) ………0.05M NaCl ………0.15M アジ化ソーダ 0.1重量% ポリオキシエチレンノニルフエニルエーテル ………7.2重量% (ii)第2試薬 SLO液 SLOの調製 A群溶連菌をトツド・ヘヴイト培地で16〜20時間培養
し、菌体を除去した上清から硫酸アンモニウム塩析によ
りSLOを得た。このSLOを0.005Mリン酸緩衝液で充分に透
析し、溶血価1000単位/mlに調整し、凍結乾燥する。
(1) Equipment used Hitachi 7050 automatic analyzer (2) Reagent (i) First reagent HEPES buffer (pH 7.2) ... 0.05 M NaCl ... 0.15 M Sodium azide 0.1 wt% polyoxyethylene nonyl Phenyl ether 7.2% by weight (ii) Second reagent SLO solution Preparation of SLO Group A streptococci were cultured in Todo-Hewitt medium for 16 to 20 hours, and SLO was removed from the supernatant from which bacterial cells were removed by ammonium sulfate salting out. Obtained. This SLO is sufficiently dialyzed against a 0.005M phosphate buffer, adjusted to a hemolysis value of 1000 units / ml, and freeze-dried.

SLO液の調製 で調製したSLOを、第1試薬と同様な成分液で溶血
価1000単位/mlとなるよう溶解し、第2試薬とした。
The SLO prepared in the preparation of the SLO solution was dissolved in the same component solution as the first reagent so as to have a hemolysis value of 1000 units / ml, and was used as a second reagent.

(3) 操作方法 上記機器及び試薬を用いて行なつた測定操作の概略を
第1図に示す。まず反応セル中に水のみ入れた、セルブ
ランクの340nmの吸光度を測定し、次いで水を排出後検
体血清20μ及び第1試薬350μを入れ、1回目の吸
光度を測定した。以後20秒間隔で計32回、10分間にわた
り測定した。ここでセルブランクの吸光度は、装置内の
演算機構により自動的に各測定値より差し引かれる。第
1試薬の添加5分後に第2試薬50μを添加し、反応を
開始させた。
(3) Operation method FIG. 1 shows an outline of the measurement operation performed using the above-described equipment and reagents. First, the absorbance at 340 nm of a cell blank in which only water was put in the reaction cell was measured. Then, after water was discharged, 20 µ of the sample serum and 350 µ of the first reagent were added, and the first absorbance was measured. Thereafter, the measurement was performed at intervals of 20 seconds for a total of 32 times for 10 minutes. Here, the absorbance of the cell blank is automatically subtracted from each measured value by an arithmetic mechanism in the apparatus. Five minutes after the addition of the first reagent, 50 µ of the second reagent was added to start the reaction.

上記各測定値の内、第19〜21回目(第2試薬添加後1
分〜1分40秒)に測定された吸光度を採り、最小二乗法
により単位時間当たりの吸光度変化量を算出した。
Of the above measured values, the 19th to 21st times (1 after addition of the second reagent)
(Min. To 1 min. 40 sec.), And the change in absorbance per unit time was calculated by the least squares method.

(4) 標準検量線の作成 ASOが陰性の血清及び280Todd単位の血清を用いて次の
希釈系列を調整した。
(4) Preparation of Standard Calibration Curve The following dilution series was prepared using ASO negative serum and 280 Todd unit serum.

希釈比 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.
8 0.9 1.0 ASO(Todd単位) 0 28 56 84 112 140 168 19
6 224 252 280 これら11種の血清20μずつを用い、上記操作方法に
従つて単位時間当たりの吸光度変化量(ΔABS/min)を
求め、ASO濃度との関係をプロツトして標準検量線を作
成した。これを第2図に示す。
Dilution ratio 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.
8 0.9 1.0 ASO (Todd unit) 0 28 56 84 112 140 168 19
6 224 252 280 Using 20 μ of each of these 11 types of sera, the amount of change in absorbance per unit time (ΔABS / min) was determined according to the above-described operation method, and the relationship with the ASO concentration was plotted to prepare a standard calibration curve. . This is shown in FIG.

(5) 結果 第3−A図及び第3−B図から明らかなように、本発
明方法は従来法との良好な相関関係を有する。
(5) Results As is clear from FIGS. 3-A and 3-B, the method of the present invention has a good correlation with the conventional method.

【図面の簡単な説明】[Brief description of the drawings]

第1図は、自動分析装置による吸光度測定手順の概略を
示す図面であり、第2図は、標準検量線を示す図面であ
る。 第3−A図は、本発明方法とラテツクス比濁法との相関
を示す図面であり、第3−B図は、本発明方法とマイク
ロタイター法との相関を示す図面である。
FIG. 1 is a drawing showing an outline of a procedure for measuring absorbance by an automatic analyzer, and FIG. 2 is a drawing showing a standard calibration curve. FIG. 3-A is a drawing showing the correlation between the method of the present invention and the latex turbidimetry, and FIG. 3-B is a drawing showing the correlation between the method of the present invention and the microtiter method.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 柴田 英昭 東京都豊島区巣鴨2丁目11番1号 日水 製薬株式会社内 (56)参考文献 特開 昭53−44623(JP,A) 特開 昭58−113758(JP,A) 特開 昭49−42822(JP,A) 特開 昭55−31960(JP,A) 特開 昭48−37184(JP,A) 特開 昭58−187862(JP,A) ──────────────────────────────────────────────────続 き Continued on the front page (72) Inventor Hideaki Shibata 2-1-1-1, Sugamo, Toshima-ku, Tokyo Nissui Pharmaceutical Co., Ltd. (56) References JP-A-53-44623 (JP, A) JP-A Sho 58-113758 (JP, A) JP-A-49-42822 (JP, A) JP-A-55-31960 (JP, A) JP-A-48-37184 (JP, A) JP-A-58-187862 (JP, A A)

Claims (3)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】検体にストレプトリジンO及びフェニル基
を有するポリオキシエチレンエーテル系非イオン性界面
活性剤を添加し、生じた凝集による吸光度変化量を測定
することを特徴とする抗ストレプトリジンOの定量法。
An anti-streptolysin O is characterized in that streptolysin O and a polyoxyethylene ether-based nonionic surfactant having a phenyl group are added to a sample, and the amount of change in absorbance caused by the resulting aggregation is measured. Assay method.
【請求項2】吸光度変化量の測定を、ストレプトリジン
O及び非イオン性界面活性剤の添加後0〜7分の間にお
こなう特許請求の範囲第1項記載の抗ストレプトリジン
Oの定量法。
2. The method for quantifying anti-streptolysin O according to claim 1, wherein the change in absorbance is measured between 0 and 7 minutes after the addition of streptolysin O and the nonionic surfactant.
【請求項3】吸光度変化量の測定を、単位時間当りの吸
光度変化量として求め、この値を最小二乗法によって処
理し算出することによりおこなう特許請求の範囲第1項
記載の抗ストレプトリジンOの定量法。
3. The method according to claim 1, wherein the measurement of the change in absorbance is obtained as a change in absorbance per unit time, and this value is processed and calculated by the least squares method. Assay method.
JP62169498A 1987-07-07 1987-07-07 Determination of anti-streptolysin O Expired - Lifetime JP2589088B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62169498A JP2589088B2 (en) 1987-07-07 1987-07-07 Determination of anti-streptolysin O

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62169498A JP2589088B2 (en) 1987-07-07 1987-07-07 Determination of anti-streptolysin O

Publications (2)

Publication Number Publication Date
JPS6413461A JPS6413461A (en) 1989-01-18
JP2589088B2 true JP2589088B2 (en) 1997-03-12

Family

ID=15887636

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62169498A Expired - Lifetime JP2589088B2 (en) 1987-07-07 1987-07-07 Determination of anti-streptolysin O

Country Status (1)

Country Link
JP (1) JP2589088B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0534043A3 (en) * 1991-09-25 1993-05-05 Biokit Sa Novel antistreptolysin-o reagent for use with beckman nephelometer system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4837184A (en) * 1971-09-10 1973-06-01
JPS4942822A (en) * 1972-09-04 1974-04-22
JPS5344623A (en) * 1976-09-30 1978-04-21 Wako Pure Chem Ind Ltd Novel immunoassay
JPS5531960A (en) * 1978-08-30 1980-03-06 Nitsusui Seiyaku Kk Latex sensing for cohesion reaction
JPS58113758A (en) * 1981-12-26 1983-07-06 Shimadzu Corp Analysis for immune globulin

Also Published As

Publication number Publication date
JPS6413461A (en) 1989-01-18

Similar Documents

Publication Publication Date Title
Teppo Immunoturbidimetry of albumin and immunoglobulin G in urine.
SU1554782A3 (en) Method of determining antigens or antibodies
US4536478A (en) Method for reducing non-specific interferences in agglutination immunoassays
AU602129B2 (en) Method for the determination of a differential white blood cell count
US4965191A (en) Lower alcohol sulfate wash solution, test kit and method for the determination of an immunological ligand
US5017474A (en) Wash solution, test kit and method for the determination of an immunological ligand
CH642750A5 (en) PROCEDURE FOR THE QUICK DETERMINATION OF IRON IN BLOOD SERUM AND MIXTURE FOR THE EXECUTION OF THE PROCEDURE.
EP0379133B2 (en) Use of divalent cations in immunochemical tests
JP2589088B2 (en) Determination of anti-streptolysin O
US3558278A (en) Determination of albumin
JPH05209199A (en) Kit and method for measuring cleaning composition and for measuring microorganism accompanying periodontosis
US4741999A (en) Monoclonal antibodies useful in the identification of microorganisms causing periodontal disease
JP2004012434A (en) Method for measuring pepsinogen and measuring kit
SU1367838A3 (en) Versions of method of determining tistreptolizene antibodies in blood
IL46338A (en) Determination of serum creatinne
US4554248A (en) Composition and method for detecting Antistreptolysin O
JPH0682450A (en) Immunological measuring reagent
JP2534067B2 (en) Quantitative method for C-reactive protein
JP3298812B2 (en) Method for measuring urinary trypsin inhibitor
EP0100395B1 (en) Reagent for determination of human urine kallikrein
JP2523332B2 (en) Antibody classification method
Powell et al. A new automated procedure for the colorimetric determination of glucose
JPH0261561A (en) Measurement of immunological reaction
JPS61182578A (en) Method and reagent for quantitative determination of anti-streptolysin o antibody
US5185128A (en) Test kit containing labeled receptor and wash solution for determination of an immunological ligand